Besides MEN1, other rare hereditary syndromes can cause pancreas NET. See our recent publication on the first family with Mahvash disease due to glucagon receptor mutations. Interesting how glucagon signaling knockout affects amino acid metabolism, not glucose. erc.bioscientifica.com/doi/10.1530/...
Finally here, the new MEN1 guideline!
@julierefardt.bsky.social @jelkakuiper.bsky.social @mickeykerolles.bsky.social @eskeww.bsky.social
New bibliometric analysis reveals that our @enets.bsky.social CoE at @erasmusmc.bsky.social is doing well in publications and collaborations in the GEP NET field. Proud of a great team and our partners! 🙏 Hope to continue and improve this in the future! www.frontiersin.org/journals/onc....
🚨 Calling all early-career NET researchers!
The Basic/Translational Science Investigator (BTSI) Award—funded by @netrf.bsky.social in partnership with @nanets.bsky.social — a $100K, 2-year grant to support innovative NEN research. Apply by June 13th.
Learn more & apply: nanets.net/research/res...
Great to see our PhD student Jelka win the best basic science mini-oral abstract award at ENETS conference on the topic of a family with Mahvash disease @enets.bsky.social
Special thanks to @enets.bsky.social for organising this inspiring meeting and bringing us all together.
Enjoyed a wonderful ENETS 2025 meeting in Krakau. Many new developments in the NET field with a great collaborative effort from many disciplines. Proud to see so many presentations from my colleagues from our ENETS Center of Excellence at Erasmus MC. Looking forward to new and exciting research.
link.springer.com/article/10.1... Good to see more molecular data in functioning NET, in this case showing added value of staining ATRX/DAXX in insulinoma and possibly the rare functioning syndromes. Anybody using this in routine practice for panNET? @koendreijerink.bsky.social #medsky #NETs
Intriguing new data of microbial 🦠 uremic toxins in MEN1 patients with duodenopancreatic NET 🦓 revealing additional associations between NET and the gut microbiome. www.sciencedirect.com/science/arti.... Similar to other cancers, it's time to take NET-microbiome research to the next level 🧬
Although you can effectively target the NEC is some cases, lutetium is not enough in series and in my limited experience. Alpha and/or combo is needed.
Metagenomic profiling of gut microbiome samples confirms differences between small intestinal NET patients and controls. Also opens up new avenues into diagnostics for carcinoid syndrome and differential microbial pathways. Out now in Endocrine Related Cancer: erc.bioscientifica.com/view/journal...
